11C methionine positron emission tomography

• Visualization of P2X7 Receptors in Living Human Gliomas: An 18F-GSK1482160 PET Imaging and Neuropathology Study
• Thyroid nodule with cytological outcome of indeterminate lesion with low risk of malignancy found to be parathyroid adenoma. A case report and minireview of literature
• Comparison of Imaging Modalities in Differentiating Cerebral Neoplastic Lesions and Post-radiation Necrosis
• Three-dimensional amide proton transfer (APT) imaging appliable to navigation surgery can present comparable metabolic activity of glioblastoma to ¹¹C-Methionine PET
• Higher Uptake of Preoperative 11C-Methionine Positron Emission Tomography Related to Preoperative Seizure in Patients With Oligodendroglioma
• Diagnostic value of 11C-Methionine PET-CT imaging in persistent or recurrent Cushing's disease after surgery
• 11C-Methionine PET/CT in Cryptococcus Meningoencephalitis
• The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review

Tumor to normal tissue ratio (T/N ratio) on 11C-methionine (11C-MET) positron emission tomography/computed tomography (PET/CT) is affected by variable factors.

11C methionine positron emission tomography for glioma.

The visual assessment showed no significant difference from quantitative assessment of MET-PET with a relevant cut-off value for the differentiation of recurrent brain tumors from radiation-induced necrosis ¹⁾.

see 11C methionine positron emission tomography for meningioma.

MET-PET is a sensitive technique for diagnosing persistent acromegaly and its coregistration with 3T MRI has demonstrated a better definition of the interface, extension and location of the lesion in the management of active postoperative acromegaly ²⁾.